EN DE
Watch Dizal (Jiangsu) Pharmaceutical Co. Ltd. A for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A stock ¥37.81, price ¥66.29, that is 43.0% below the price, quality 36 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE1000055W8

DJ Dizal (Jiangsu) Pharmaceutical Co. Ltd. A logo Thin data Nov 10, 2026

Dizal (Jiangsu) Pharmaceutical Co. Ltd. A

688192 · SHG
Very expensive, weak quality

Our calculation puts a fair price 43% below what the stock costs today.

Revenue last quarter +38% vs. a year ago.
Mixed Growth (revenue 5y +95.9 %/yr in CNY)
Moderate debt
Fair value ¥37.81 · Strongly overvalued
Quality 36/100
Loss-making · -61.6% net margin (TTM)
Negative free cash flow
Trails peers (1/11)
Narrow moat 12/100
Thin data
Estimate
Watch Dizal (Jiangsu) Pharmaceutical Co. Ltd. A for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥85.21 ¥19.60 Fair Value ¥37.81 Dec 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

59‑month range ¥19.60 – ¥85.21 · fair‑value band ¥28.36 – ¥47.26 · the ¥66.29 price screens above the ¥37.81 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Dizal (Jiangsu) Pharmaceutical Co. Ltd. A in your weekly email

Every Wednesday you see whether Dizal (Jiangsu) Pharmaceutical Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Dizal (Jiangsu) Pharmaceutical Co., Ltd., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of oncology and hematologic disorders.

Show moreShow less

Its assets include the ZEGFROVY, for the treatment of solid tumors; Gao Ruizhe to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors.

Dizal (Jiangsu) Pharmaceutical Co., Ltd. was founded in 2017 and is based in Shanghai, China.

Stock analysis

Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192) currently trades at ¥66.29, while our estimate is ¥37.81, 43% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: ¥28.36 (bear) to ¥47.26 (bull), the price of ¥66.29 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Dizal (Jiangsu) Pharmaceutical Co. Ltd. A reported revenue of 801M CNY in FY2025 versus 10.3M CNY in FY2021, a compound +197.1%/yr. Reported net income was −764M CNY in FY2025.

Key figures

Market cap 30.6B CNY (≈ $4.6B) Mid · P/S ratio 26.6 · EPS (TTM) ¥−1.23 · Dividend yield 0.1% · Net margin −61.6% · Return on equity −43.7% · Return on assets (EBIT) −43.3% (5-year average) · Operating margin −45.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 2% below its 52-week high and 82% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −43%, 688192 screens richer than that median.

Fair Value

Bear ¥28.36 Fair Value ¥37.81 Bull ¥47.26
Price ¥66.29 · Downside -43.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 36/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 11
How much profit the company makes from its sales and capital
Quality Growth 82
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 64
Debt, balance sheet and risk of trouble
Investment 45
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 55
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 68
Distance to the 52-week high, does not count
New shares 20
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 28/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+122.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+95.9%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+64.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,739.0% (2020) → −94.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

688192 screens overvalued: fair value 43% below the price. Compare with Merck KGaA →

Compare Dizal (Jiangsu) Pharmaceutical Co. Ltd. A with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 1/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 36 · Bottom 25%
Fair Value upside −43.0% · Below median
Profitability
Return on assets −25.5% · Bottom 25%
Net margin (12 months) −61.6% · Bottom 25%
Operating margin (12 months) −45.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 38.3% · Top 25%
Dividend yield (12 months) 0.1% · Bottom 25%
Balance sheet
Debt / equity 0.53× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 23.63× · Priciest 25%
P/S (12 months) 31.56× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 18
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)73 · sector 96
DIVIDEND (yield)3 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.46 $113.53 +38% vs 688192
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs 688192
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs 688192
Haleon plc HLN $9.06 $8.62 −5% vs 688192
Merck KGaA MRK €149.35 €109.18 −27% vs 688192
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs 688192
Takeda Pharmaceutical Company TAK $20.93 $11.34 −46% vs 688192
Teva Pharmaceutical Industries Limited TEVA $42.40 $20.74 −51% vs 688192
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs 688192
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs 688192

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Dizal (Jiangsu) Pharmaceutical Co. Ltd. A: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Dizal (Jiangsu) Pharmaceutical Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/688192

Frequently asked questions

Is Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is ¥37.81 versus a price of ¥66.29, about 43% lower (overvalued).
What is the fair value of 688192?
Our estimate for Dizal (Jiangsu) Pharmaceutical Co. Ltd. A is ¥37.81 (as of Nov 10, 2026), built from audited fundamentals. The current price: ¥66.29.
What is the quality score of 688192?
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192)?
Our calculated price target is the estimate of ¥37.81 (as of Nov 10, 2026). Cautious scenario ¥28.36, optimistic scenario ¥47.26. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Dizal (Jiangsu) Pharmaceutical Co. Ltd. A stock forecast for 2026?
Our estimate puts fair value at ¥37.81, about 43% lower versus a price of ¥66.29 (overvalued). Cautious scenario ¥28.36, optimistic scenario ¥47.26. The calculation is refreshed regularly with new filings.
What is the revenue of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192)?
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A reported trailing-twelve-month revenue of about 969M CNY (latest available figure, as of Nov 10, 2026).
Does Dizal (Jiangsu) Pharmaceutical Co. Ltd. A pay a dividend?
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A currently shows a dividend yield of 0.13% relative to its recent price (as of Nov 10, 2026).
How much is the dividend of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192)?
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A has a dividend yield of 0.1%.
What is the intrinsic value of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Dizal (Jiangsu) Pharmaceutical Co. Ltd. A it is ¥37.81 per share (as of Nov 10, 2026), against a price of ¥66.29.
Is Dizal (Jiangsu) Pharmaceutical Co. Ltd. A stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 688192 trades above its calculated fair value: price ¥66.29, fair value ¥37.81, a gap of about −43% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688192?
No. The price is what the market pays today (¥66.29); the fair value is what the company's own numbers justify (¥37.81). For Dizal (Jiangsu) Pharmaceutical Co. Ltd. A the two are ¥28.48 per share apart. That gap is exactly why we show both numbers side by side.
How much is Dizal (Jiangsu) Pharmaceutical Co. Ltd. A worth?
The market values Dizal (Jiangsu) Pharmaceutical Co. Ltd. A at about 30.6B CNY (market capitalisation, as of Nov 10, 2026). Per share that is ¥66.29; our models calculate a fair value of ¥37.81 per share.
What do the bullish and bearish scenarios say about 688192?
Our models span a range for Dizal (Jiangsu) Pharmaceutical Co. Ltd. A: cautious scenario ¥28.36, base ¥37.81, optimistic ¥47.26 per share (as of Nov 10, 2026, price ¥66.29). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192)?
Balance-sheet figures for Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (as of Nov 10, 2026): return on equity −43.7%, debt of 0.53 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is 688192 from its 52-week high?
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A trades at ¥66.29, about 2% below its 52-week high of ¥67.97 and 82% above the low of ¥36.49 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of ¥37.81 is for.
Which stocks are comparable to Dizal (Jiangsu) Pharmaceutical Co. Ltd. A?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Dizal (Jiangsu) Pharmaceutical Co. Ltd. A stock attractive at the current price?
The data as of Nov 10, 2026: price ¥66.29, calculated fair value ¥37.81 (−43%), Quality Score 36/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Dizal (Jiangsu) Pharmaceutical Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192)?
The closing price on Nov 10, 2026 was ¥66.29. Our estimate is ¥37.81, about 43% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Dizal (Jiangsu) Pharmaceutical Co. Ltd. A right now?
The price sits above even our optimistic bull case (¥47.26). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A

How large is the market capitalisation of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192)?
The market capitalisation of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A is 30.6B CNY (≈ $4.6B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192)?
The price-to-sales ratio of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A is 26.6 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192)?
Earnings per share at Dizal (Jiangsu) Pharmaceutical Co. Ltd. A are ¥−1.23. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192)?
The dividend yield of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A is 0.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192)?
The net margin of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A is −61.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192)?
The return on equity (ROE) of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A is −43.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192)?
On an EBIT basis the return on assets of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A is −43.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192)?
The operating margin of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A is −45.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192)?
Revenue at Dizal (Jiangsu) Pharmaceutical Co. Ltd. A is growing +38.3% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192) generate?
The free cash flow of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A is −759M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192) carry?
The net debt of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A is 614M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Dizal (Jiangsu) Pharmaceutical Co. Ltd. A in the live analysis

One click puts Dizal (Jiangsu) Pharmaceutical Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.